Inclisiran

證據等級: L5

預測適應症: 10 個

Inclisiran: From Hypercholesterolemia to Potassium Deficiency Disease

One-Sentence Summary

Inclisiran (DB14901) is a PCSK9-targeted siRNA; its originally approved indication is not captured in this evidence pack (Norway licensing data is empty — the drug is currently not marketed). TxGNN's top-ranked prediction in this batch is Potassium Deficiency Disease (score 99.93%), but this signal is supported by 0 clinical trials and 0 publications — it is a pure model artifact with no biological rationale, and the internal scoring engine itself flags it as Hold.

Quick Overview

Item	Content
Original Indication	Not available — `taiwan_regulatory.licenses` is empty in this evidence pack. (General pharmacological background, not from this dataset: inclisiran is a PCSK9-directed siRNA used for LDL-C lowering/ASCVD risk reduction.)
Predicted New Indication	Potassium deficiency disease
TxGNN Prediction Score	99.93%
Evidence Level	L5 (model prediction only, no supporting studies)
Norway Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for inclisiran in this evidence pack (original_moa: [Data Gap]). Based on general pharmacological knowledge, inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 mRNA translation, thereby increasing LDL-receptor recycling and lowering circulating LDL cholesterol.

For the top-ranked prediction in this batch — potassium deficiency disease — the evidence pack's own mechanistic assessment explicitly states there is no known biological relationship between the PCSK9/LDL-receptor pathway and potassium homeostasis, and no trial or literature evidence exists to support the link. This is consistent with a high TxGNN embedding-similarity score that does not correspond to plausible pharmacology — a known failure mode of pure graph-embedding predictions when unconstrained by mechanistic filters.

Given this, the prediction should not be interpreted as a genuine repurposing signal. It is retained in this report for transparency and audit purposes only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Inclisiran is currently not marketed in Norway — taiwan_regulatory.market_status = "未上市", with 0 authorizations on file. No license records are available to summarize.

Other Candidates in This Batch (Context)

This evidence pack ("TW-DB14901-multi") contains 10 TxGNN-ranked predictions for inclisiran, most of which share the same problem as the top hit — high score, zero evidence, "Hold." One candidate stands out as materially different and warrants separate follow-up:

Rank	Disease	TxGNN Score	Evidence Level	Decision Stage	Recommendation	Note
1	Potassium deficiency disease	99.93%	L5	S0	Hold	No mechanistic link, no evidence
2	Esophageal disease	99.87%	L5	S0	Hold	No evidence
4	Migraine disorder	99.83%	L5	S0	Hold	No evidence
7	Migraine w/ or w/o aura, susceptibility	99.78%	L5	S0	Hold	20 papers retrieved, but all on epilepsy/migraine genetics — none address PCSK9/lipid pathways
8	Aortic malformation	99.76%	L4	S1	Research Question	2 active Phase 3 pediatric FH trials (NCT06597006, NCT06597019); plausible mechanistic link via LDL-C-driven vascular/valvular lipid deposition, but trial inclusion criteria (HoFH/HeFH) need manual verification against "aortic malformation" as a MeSH-level term
9	Esophageal ulcer	99.73%	L5	S0	Hold	No evidence
10	Raynaud disease	99.73%	L5	S0	Hold	No evidence

Rank 8 ("aortic malformation") is the only candidate in this batch that reached decision stage S1 with real clinical trial backing, and is the more appropriate target for a dedicated follow-up evaluation report — not the top-ranked "potassium deficiency disease" entry.

Safety Considerations

Please refer to the package insert for safety information. safety.key_warnings, safety.contraindications, and safety.ddi are all marked as data gaps in this evidence pack (see DG001, "Blocking" severity — TFDA/label warnings not yet retrieved).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (potassium deficiency disease) has a very high TxGNN score but zero corroborating clinical or literature evidence, and the pack's own rationale confirms no biological plausibility. This is a model-artifact signal, not a genuine repurposing candidate.

To proceed, the following is needed:

Resolve DG001 (Blocking): retrieve TFDA/Norway label warnings and contraindications before any S1 safety screening can begin for this drug
Resolve DG002 (High): pull structured MOA data from DrugBank to properly evaluate mechanistic plausibility across all candidates
If continuing repurposing exploration for inclisiran, redirect focus to rank 8 (aortic malformation) — verify actual inclusion criteria of NCT06597006/NCT06597019 against the predicted indication term before advancing to S2
Populate taiwan_regulatory.licenses / original_indications — currently empty, blocking a complete original-vs-new indication comparison
Do not advance "potassium deficiency disease," "esophageal disease/ulcer/malformation," "migraine," or "Raynaud disease" without new supporting evidence — all currently L5/Hold
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.